If you are looking for an answer to the question What is Artificial Intelligence? and you only have a minute, then here's the definition the Association for the Advancement of Artificial Intelligence offers on its home page: "the scientific understanding of the mechanisms underlying thought and intelligent behavior and their embodiment in machines."
However, if you are fortunate enough to have more than a minute, then please get ready to embark upon an exciting journey exploring AI (but beware, it could last a lifetime) …
A report on the public perception of self-driving vehicles in the United States found that 62% of people surveyed believe autonomous vehicles are the way of the future, and that enthusiasm for those vehicles has risen since the onset of the COVID-19 pandemic. The survey of more than 1,000 Americans and its accompanying Consumer Mobility Report comes from Motional, a driverless technology company created by Hyundai and Aptive. Motional was created to work on commercial uses of SAE level four vehicles, which are fully autonomous and able to perform all tasks from the beginning to the end of a trip. Along with finding enthusiasm for driverless vehicles rising, Motional also found that there's a knowledge gap around self-driving vehicles that plays directly into an enthusiasm gap. Respondents who rated themselves extremely knowledgeable about autonomous vehicles were far more likely to believe that those on the road to day are safe and reliable (76%), versus those that said they are less knowledgeable, of whom only 10% said current self-driving vehicles are safe.
Collaboration Will Allow Care Providers on Amwell Platform to Remotely Examine Patients Using Streaming Information From Tyto Devices, Extending the Scope of Care Rendered at Home. Amwell, a national telehealth leader, announced it is expanding its partnership with Tyto Care, the healthcare industry's first all-in-one modular device and examination platform for AI-powered, on-demand, remote medical exams. Together the companies will introduce exclusive integrations and newly designed workflows and tools to enhance the ability for providers using the Amwell platform to examine and diagnose patients virtually. Additionally, Amwell will become a reseller of Tyto Care's integrated devices. By pairing the TytoHome handheld examination device – which enables on-demand examinations of the heart, lungs, abdomen, skin, throat, ears, heart rate, and body temperature – with Amwell's telehealth platform, providers can guide patients through virtual health examinations and together gain real-time insight into a patient's health data and status directly in the visit.
SS&C Health to Offer Wiseman's Payer and EHR Agnostic Platform for Provider Intelligence SS&C Technologies Holdings, Inc. announced that it has partnered with Wiseman Innovations, LLC, a population health technology company. SS&C will be an independent, authorized reseller of Wiseman's 360PlatformTM to health payers and providers. The payer-agnostic platform delivers value-based analytics to providers at the point of care within their existing electronic health/medical record (EHR/EMR) system. "Wiseman's proven technology is complementary to SS&C Health's health optimization suite and builds on the momentum surrounding our population health tools," said SS&C Health's President, Daniel Del Mastro. "The offering increases the payer-provider alignment and trust crucial in the risk-sharing arrangements of value-based care programs. Together, we deliver the scalable and interoperable solutions that are needed for sustainable results in value-based care."
And we're just getting started. As we grow and develop a long-term product strategy around our use of data and AI, we acknowledge our responsibility to create a values-based system to guide how we use and develop AI. By applying learnings from Google's Responsible Innovation team, we created a set of principles to ensure that we develop models that avoid reinforcing unfair bias that impacts people based on their ethnicity, sexual orientation, gender identity, race, and the intersection of these identities. I joined The Trevor Project because it's an organization driven by values, and our use of technology reflects this. I noticed an opportunity to leverage my years of experience and partner with people who are committed to employing technology for social good.
Since it launched in 2018, Facebook's machine learning framework PyTorch has been put to good use, with applications ranging from powering Elon Musk's autonomous cars to driving robot farming projects. Now pharmaceutical firm AstraZeneca has revealed how its in-house team of engineers are tapping PyTorch too, and for equally as important endeavors: to simplify and speed up drug discovery. Combining PyTorch with Microsoft Azure Machine Learning, AstraZeneca's technology can comb through massive amounts of data to gain new insights about the complex links between drugs, diseases, genes, proteins or molecules. Those insights are used to feed an algorithm that can, in turn, recommend a number of drug targets for a given disease for scientists to test in the lab. The method could allow for huge strides in a sector like drug discovery, which so far has been based on costly and time-consuming trial-and-error methods.
There was plenty of product and technology news from across the application portfolio to coincide with yesterday's Oracle Live virtual event. Oracle has not only been moving its core applications to the cloud these past few years. The enterprise software vendor has also been transitioning its business operations to support the kind of continuous engagement with customers that is characteristic of the SaaS and cloud model. One big example of that shift has been the recent move to combine support, service and product development for applications into a single organization reporting to Steve Miranda, EVP of Oracle Applications Product Development. The aim is to have a single customer success manager responsible for each customer, while still drawing on expert resources across the product set that's applicable for that customer.
DBC team has posted a message on their twitter account which says that the Deep Brain Chain AI Machines are ready for delivery to all miners who have not had their machines delivered. By this, Deep Brain Chain Foundation has fulfilled its original promise to upgrade the GPU servers from Nvidia GTX 1080Ti to Nvidia RTX 2080Ti. In addition, Deep Brain Chain foundation has already found customers for the miner's machines and it is possible to lease out the machines, if needed. The buyers of the mining machines are required to reply back to their emails in order to complete the delivery which will be completed within 7 working days. If you have received a message about this on telegram, you must send an email to email@example.com to confirm.
You may have missed it, but the Association for the Advancement of Artificial Intelligence (AAAI) just announced its first annual Squirrel AI award winner: Regina Barzilay, a professor at MIT's Computer Science and Artificial Intelligence Laboratory (CSAIL). In fact, if you're like me, you may have missed that there was a Squirrel AI award. But there is, and it's kind of a big deal, especially for healthcare -- as Professor Barzilay's work illustrates. The Squirrel AI Award for Artificial Intelligence for the Benefit of Humanity (Squirrel AI is a Chinese-based AI-powered "adaptive education provider") "recognizes positive impacts of artificial intelligence to protect, enhance, and improve human life in meaningful ways with long-lived effects." The award carries a prize of $1,000,000, which is about the same as a Nobel Prize.
AI presents a promising development in the fight against diseases and other health conditions. TAMJID AIJAZI of Makeen Technologies looks at some ways artificial intelligence is already changing the healthcare industry. According to some estimates, the AI in the healthcare market is expected to reach $15.96 billion by 2024. Healthcare has always been a field where cutting-edge technology can have a huge impact. Recent advancements in science and technology have brought us closer to a world where virtually any illness can be cured.
Companies are planning to increase their spending on artificial intelligence and machine learning as a result of the pandemic, and IT leaders believe that those initiatives should have been a higher priority for their organizations all along, according to a newly released survey by Algorithmia, a provider of ML operations and management platforms. Algorithmia's "2020 Enterprise AI/ML Trends" survey was completed in August by over 100 IT directors and above who are involved with those initiatives and work in companies with at least $1 billion in annual sales and 5,000 or more employees, the company said. There is little doubt the events of the past six-plus months have disrupted the plans of IT organizations. In fact, 42% of IT leaders responding to Algorithmia's survey said that at least half of all their AI/ML projects were impacted from a priority, staffing, or funding standpoint because of the COVID-19 pandemic. SEE: Microsoft's new feature uses AI to make video chat less weird (TechRepublic) But that doesn't mean those projects are going away--instead, their focus may have shifted, Algorithmia said. For example, 54% of IT leaders said their projects were focused on financial analysis and consumer insight prior to the pandemic.